Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.64 |
| ▸ | BRAF | P15056 | 4/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.60 |
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.56 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.56 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL365495 | 0.87 | PLA2G7 (0.53) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL9106278 | 0.85 | ESRRA (0.57) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL16319640 | 0.85 | BRAF (0.57) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL365662 | 0.83 | CHEK2 (0.51) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL364772 | 0.83 | RAF1 (0.53) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL1086197 | 0.82 | NPFFR2 (0.58) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL31144967 | 0.82 | NPFFR2 (0.58) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL4383135 | 0.81 | NPFFR2 (0.56) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL30536926 | 0.81 | NPFFR2 (0.56) | CHEK2BRAFHDAC1HDAC3HDAC4 | |
| SCHEMBL15094332 | 0.80 | SCN9A (0.66) | CHEK2BRAFHDAC1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2593427-B1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LTD (GB) | 2014-12-24 | — | — | EP | disclosed |
| EP-2593427-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | CHEK2 4544/4885BRAF 514/4885HDAC1 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.